Role of Prohepcidin in Uremic Patients

Haseki Training and Research Hospital

Status: Completed

Conditions: Chronic Kidney Disease; Inflammation

Study type: Observational

Funder types: Other

Identifiers

NCT01735773

HEPCIDIN-HASEKI

Details and patient eligibility

About

The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.

Enrollment: 25 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• hemodialysis and peritoneal dialysis patients who had been on dialysis therapy for more than 3 months,
• age between 18-80 years,
• patients with creatinine clearance between 15-30 ml/min.

Exclusion criteria

• age less than 18 or more than 80,
• diabetic patients,
• current active infectious or inflammatory disease.

Trial design

25 participants in 4 patient groups

Hemodialysis group

Description:

Patients on chronic hemodialysis program

Peritoneal dialysis group

Description:

Patients on chronic peritoneal dialysis program

Pre-dialysis group

Description:

Patients with chronic kidney disease stage-4

Control group

Description:

Healthy volunteers